{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:49Z","timestamp":1791355789993,"version":"4.3.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug Saf. Regul."],"abstract":"<jats:p>Tirzepatide was introduced several years ago for the management of obesity. Its side-effect profile includes gastrointestinal symptoms and hormonal shifts similar to other glucagon-like peptide-1 receptor agonists (GLP-1RAs). This class of medications is currently being investigated for its potential utility in treating depressive and anxiety disorders. While safety data generally indicate a low risk for adverse psychiatric events - such as suicidal ideation or depressive episodes - and some evidence suggests a beneficial impact on mood, anecdotal reports have linked these agents to panic attacks. However, scientific evidence for this remains limited. We present the cases of two female patients with histories of depressive disorder who experienced panic attacks following tirzepatide injections for weight loss. Both required hospitalization for the exacerbation of moderate-to-severe recurrent depressive disorder. The panic attacks occurred in close temporal proximity to the injections and resolved upon discontinuation. No clear medical aetiology was identified. Changes in pharmacokinetics by delayed gastric emptying, GABAergic deficits, an activation of the nucleus of the solitary tract (NTS) or activation of the hypothalamus-pituitary-adrenal axis are considered as potential mechanisms for panic attacks.<\/jats:p>","DOI":"10.3389\/fdsfr.2026.1880796","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:53:32Z","timestamp":1791352412000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Panic attacks after tirzepatide injection in two female patients with recurrent depressive disorder"],"prefix":"10.3389","volume":"6","author":[{"given":"Ulrich","family":"Palm","sequence":"first","affiliation":[{"name":"P3 Klinik, Private Clinic for Psychiatry, Psychotherapy and Psychosomatics","place":["Tutzing, Germany"]},{"name":"Department of Psychiatry and Psychotherapy, Klinikum der Universit\u00e4t M\u00fcnchen","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Backmund","sequence":"additional","affiliation":[{"name":"P3 Klinik, Private Clinic for Psychiatry, Psychotherapy and Psychosomatics","place":["Tutzing, Germany"]},{"name":"Department of Psychiatry and Psychotherapy, Klinikum der Universit\u00e4t M\u00fcnchen","place":["Munich, Germany"]},{"name":"PIT, Praxiszentrum im Tal","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubertus","family":"Himmerich","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Centre for Research in Eating and Weight Disorders (CREW), Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London","place":["London, United Kingdom"]},{"name":"South London and Maudsley NHS Foundation Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e194744","DOI":"10.1172\/JCI194744","article-title":"GLP-1 physiology and pharmacology along the gut-brain axis","volume":"136","author":"Beutler","year":"2026","journal-title":"J. Clinical Investigation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"E528","DOI":"10.1152\/ajpendo.00330.2023","article-title":"The antiemetic actions of GIP receptor agonism","volume":"326","author":"Borner","year":"2024","journal-title":"Am. Journal Physiology. Endocrinol. Metabolism"},{"key":"B3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World health organization guideline on the use and indications of glucagon-like Peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am. Journal Geriatric Psychiatry Official Journal Am. Assoc. Geriatric Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet London, Engl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3390\/nu12113304","article-title":"Glucagon-like Peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress","volume":"12","author":"Diz-Chaves","year":"2020","journal-title":"Nutrients"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DHPS.S556918","article-title":"Adverse events associated with tirzepatide: updated pharmacovigilance analysis using FAERS (2022 Q1-2025 Q1) with an adapted time-to-onset method","volume":"18","author":"Gu","year":"2026","journal-title":"Drug, Healthcare Patient Safety"},{"key":"B8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/JCP.0000000000001869","article-title":"Glucagon-like peptide 1 receptor agonists in psychiatry","volume":"44","author":"Himmerich","year":"2024","journal-title":"J. Clin. Psychopharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1229086","DOI":"10.1080\/23312025.2016.1229086","article-title":"The physiological role of the brain GLP-1 system in stress","volume":"2","author":"Holt","year":"2016","journal-title":"Cogent Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J. Clinical Endocrinology Metabolism"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat. Metabolism"},{"key":"B12","doi-asserted-by":"publisher","first-page":"25cr03931","DOI":"10.4088\/PCC.25cr03931","article-title":"Mental health effects of tirzepatide: a report of 2 patients","volume":"27","author":"Mudd","year":"2025","journal-title":"Primary Care Companion CNS Disorders"},{"key":"B13","doi-asserted-by":"publisher","first-page":"bvaf150","DOI":"10.1210\/jendso\/bvaf150","article-title":"GLP-1R agonists for weight loss in psychiatric disorders: a systematic review and meta-analysis","volume":"9","author":"M\u00fcller Alves","year":"2025","journal-title":"J. Endocr. Soc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e13717","DOI":"10.1111\/obr.13717","article-title":"Potent incretin-based therapy for obesity: a systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety","volume":"25","author":"M\u00fcllertz","year":"2024","journal-title":"Obes. Reviews An Official Journal Int. Assoc. Study Obes."},{"key":"B15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.orcp.2015.03.005","article-title":"Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - a pilot study","volume":"9","author":"Robert","year":"2015","journal-title":"Obes. Research and Clinical Practice"},{"key":"B16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database","volume":"46","author":"Tobaiqy","year":"2024","journal-title":"Int. Journal Clinical Pharmacy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"765446","DOI":"10.3389\/fphar.2022.765446","article-title":"Decreased risk of anxiety in diabetic patients receiving glucagon-like Peptide-1 receptor agonist: a nationwide, population-based cohort study","volume":"13","author":"Tsai","year":"2022","journal-title":"Front. Pharmacology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/oby.70122","article-title":"Psychiatric safety of tirzepatide in people with obesity and no known major psychopathology: a post hoc analysis of SURMOUNT","volume":"34","author":"Wadden","year":"2026","journal-title":"Obes. (Silver Spring, Md.)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1626103","DOI":"10.3389\/fpsyt.2025.1626103","article-title":"Association of tirzepatide and the risk of suicide in a real-world cohort","volume":"16","author":"Yu","year":"2025","journal-title":"Front. Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fphys.2014.00238","article-title":"The nucleus of the solitary tract and the coordination of respiratory and sympathetic activities","volume":"5","author":"Zoccal","year":"2014","journal-title":"Front. Physiology"}],"container-title":["Frontiers in Drug Safety and Regulation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdsfr.2026.1880796\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:53:33Z","timestamp":1791352413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdsfr.2026.1880796\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":20,"alternative-id":["10.3389\/fdsfr.2026.1880796"],"URL":"https:\/\/doi.org\/10.3389\/fdsfr.2026.1880796","relation":{},"ISSN":["2674-0869"],"issn-type":[{"value":"2674-0869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1880796"}}